Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Nanjing Bioheng Biotech Co. Ltd. currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both of these actions are assigned to 1 distinct examiner, PETERS, ALEC JON. Consequently, PETERS, ALEC JON is the busiest examiner for the company with 2 pending actions.
The prosecution is entirely concentrated within 1 distinct art unit. This indicates that the company's current patent applications are technically similar enough to be grouped together under a single examiner and art unit. For practitioners, this means that the outcomes of both pending actions are highly dependent on the individual examination style and technical interpretation of PETERS, ALEC JON.
With 2 pending office actions and only 1 distinct examiner, the company has a highly centralized prosecution profile. There is no variance in examiner or art unit across the current portfolio. Success in the Biotechnology & Pharmaceuticals area for this company relies on effectively navigating the 2 pending actions with this single examiner in the 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PETERS, ALEC JON | 2 | 66.7% | +54.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17802242 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | PETERS, ALEC JON | 38d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015544 | ENGINEERED IMMUNE CELL FOR ALLOTRANSPLANTATION | PETERS, ALEC JON | 50d overdue |
| 17802242 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | PETERS, ALEC JON | 38d overdue |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18015544 | ENGINEERED IMMUNE CELL FOR ALLOTRANSPLANTATION | PETERS, ALEC JON | 1641 | §103 | Non-Final OA | 50d overdue | Pending | Jan 11, 2023 |
| 17802242 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | PETERS, ALEC JON | 1641 | §102§103§112 | Non-Final OA | 38d overdue | Pending | Aug 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial